DNA Biomed Solns (DNA) — Cash Flow-to-Debt Ratio
DNA Biomed Solns (DNA) has a Cash Flow-to-Debt Ratio of -0.16x as of June 2023, meaning its operating cash flow of ILA-265.00K could theoretically repay 0% of its total liabilities (ILA1.67 Million) in one year. Explore DNA long-term investments to assets to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
DNA Biomed Solns Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for DNA Biomed Solns across 12 annual periods. Also explore DNA total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for DNA Biomed Solns (2013–2024)
Year-by-year debt coverage analysis for DNA Biomed Solns. For market capitalisation and broader financial context, see market cap of DNA Biomed Solns.
| Year | CF-to-Debt Ratio | Operating CF (ILA) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.57x | ILA1.61 Million | ILA2.81 Million | ▲ +224.1% |
| 2023 | -0.46x | ILA-678.00K | ILA1.47 Million | ▼ -145.0% |
| 2022 | -0.19x | ILA-354.00K | ILA1.88 Million | ▲ +97.7% |
| 2021 | -8.12x | ILA-2.33 Million | ILA287.00K | ▼ -13914.7% |
| 2020 | -0.06x | ILA-611.00K | ILA10.54 Million | ▲ +63.9% |
| 2019 | -0.16x | ILA-1.37 Million | ILA8.55 Million | ▼ -52.9% |
| 2018 | -0.11x | ILA-1.66 Million | ILA15.81 Million | ▲ +50.4% |
| 2017 | -0.21x | ILA-1.91 Million | ILA8.99 Million | ▼ -80.2% |
| 2016 | -0.12x | ILA-14.30 Million | ILA121.59 Million | ▲ +72.7% |
| 2015 | -0.43x | ILA-15.57 Million | ILA36.10 Million | ▼ -8.6% |
| 2014 | -0.40x | ILA-10.99 Million | ILA27.68 Million | ▲ +29.5% |
| 2013 | -0.56x | ILA-5.17 Million | ILA9.19 Million | — |